QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: Newsfilter
- Overview of HDFN: HDFN is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advances in screening and treatment, inconsistencies in awareness and management persist.
- Impact of Awareness Gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delays in understanding and care, which negatively affects maternal and fetal health, highlighting the need for increased awareness.
- Importance of Laboratory Testing: Antibody screening and titers directly guide pregnancy management and risk assessment, with timely testing results significantly improving health outcomes for mothers and babies.
- Patient Perspective: By connecting diagnostic workflows to real-world outcomes, the discussion emphasizes opportunities to enhance care, particularly in well-resourced healthcare settings where timely access to expertise is crucial.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QDEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QDEL
Wall Street analysts forecast QDEL stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 13.130
Low
35.00
Averages
35.00
High
35.00
Current: 13.130
Low
35.00
Averages
35.00
High
35.00
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Optix and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AtriCure Shares Surge 6.2% Amid Renewed Investor Optimism
- Price Surge Explanation: AtriCure (ATRC) shares rose 6.2% in the last trading session to close at $28.8, primarily due to a notable increase in trading volume, reflecting renewed investor optimism regarding the company's long-term growth prospects.
- Growth Target Reaffirmed: During the Goldman Sachs Global Healthcare Conference, AtriCure's management reiterated its goal of reaching $1 billion in revenue by 2030 and highlighted the market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials, further boosting investor confidence.
- Strong Earnings Expectations: The company is expected to report quarterly earnings of $0.03 per share, representing a 250% year-over-year increase, with revenues projected at $151.5 million, an 11.3% increase from the previous year, showcasing robust performance in the medical device sector.
- Market Dynamics Attention: Although the consensus EPS estimate has remained unchanged over the past 30 days, stock price movements are often correlated with trends in earnings estimate revisions, prompting investors to monitor AtriCure's future earnings dynamics to assess the sustainability of the recent price increase.
See More
QuidelOrtho Partners with Allo Hope Foundation to Enhance Prenatal Care
- Clear Collaboration Goals: QuidelOrtho's partnership with the Allo Hope Foundation aims to enhance prenatal care through education and early testing, particularly addressing maternal red blood cell alloimmunization, a serious and often misunderstood condition, which is expected to significantly improve care quality for underserved populations.
- Educational Resource Development: The two organizations will jointly develop a series of educational materials set to launch this summer, aimed at increasing awareness among healthcare providers and ensuring women receive informed and equitable prenatal testing and care from the outset, which is anticipated to enhance overall patient experience.
- Patient-Centered Commitment: The Allo Hope Foundation emphasizes a patient-centered approach, and through collaboration with QuidelOrtho, combines clinical expertise with lived experiences to provide accurate and compassionate education, striving to support more families earlier in their journey.
- Global Impact Expansion: This collaboration not only enhances QuidelOrtho's influence in maternal health but also promotes global awareness and response to HDFN by increasing public understanding of red blood cell alloimmunization, aiming to standardize survival outcomes for affected children.
See More
QuidelOrtho Partners with Allo Hope Foundation to Enhance Prenatal Care
- Clear Collaboration Goals: QuidelOrtho and the Allo Hope Foundation aim to enhance prenatal care through education, early testing, and stronger connections among laboratory providers, clinicians, and patients, particularly addressing maternal red blood cell alloimmunization issues.
- Focus on Underserved Populations: This partnership seeks to bridge information gaps, providing clear and actionable insights for underserved populations facing challenges in prenatal care, thereby reducing risks associated with a lack of early testing.
- Development of Educational Resources: The organizations plan to release a series of co-produced educational materials this summer, designed to raise awareness among lab technicians and families, ensuring mothers receive timely, accurate testing and support.
- Patient Experience Priority: The Allo Hope Foundation emphasizes the importance of patient experience, and through collaboration with QuidelOrtho, aims to combine clinical expertise with lived experiences to provide more human-centered education and support, making survival for HDFN children the standard.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: Hemolytic disease of the fetus and newborn (HDFN) is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advancements in screening and treatment, gaps in awareness and management persist.
- Podcast Content: Episode 58 of QuidelOrtho's Science Bytes podcast, hosted by Global Product Manager Michelle Mullens, features Bethany Weathersby, Founder of the Allo Hope Foundation, discussing the impact of red blood cell antibodies on pregnancy and the importance of clinical management.
- Importance of Laboratory Testing: The podcast emphasizes the critical role of laboratory testing in prenatal care decisions, highlighting that timely results can significantly improve outcomes for mothers and babies, particularly in well-resourced healthcare settings.
- Global Awareness Initiatives: The Allo Hope Foundation is dedicated to raising global awareness of HDFN, providing patient counseling, facilitating specialty referrals, and conducting disease research to ensure that survival from HDFN becomes a global expectation.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: HDFN is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advances in screening and treatment, inconsistencies in awareness and management persist.
- Impact of Awareness Gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delays in understanding and care, which negatively affects maternal and fetal health, highlighting the need for increased awareness.
- Importance of Laboratory Testing: Antibody screening and titers directly guide pregnancy management and risk assessment, with timely testing results significantly improving health outcomes for mothers and babies.
- Patient Perspective: By connecting diagnostic workflows to real-world outcomes, the discussion emphasizes opportunities to enhance care, particularly in well-resourced healthcare settings where timely access to expertise is crucial.
See More
QuidelOrtho Corporation to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: QuidelOrtho's management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 12:20 PM ET, aiming to attract investor interest in its innovative in vitro diagnostic products.
- Fireside Chat Event: On June 3, 2026, at the Jefferies Global Healthcare Conference, QuidelOrtho's management will participate in a fireside chat at 8:10 AM ET, further showcasing the company's market strategy and future development direction.
- Live Webcast Access: Interested investors can access the live webcast and replay of the conferences through the
See More
AtriCure Shares Surge 6.2% Amid Renewed Investor Optimism
- Price Surge Explanation: AtriCure (ATRC) shares rose 6.2% in the last trading session to close at $28.8, primarily due to a notable increase in trading volume, reflecting renewed investor optimism regarding the company's long-term growth prospects.
- Growth Target Reaffirmed: During the Goldman Sachs Global Healthcare Conference, AtriCure's management reiterated its goal of reaching $1 billion in revenue by 2030 and highlighted the market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials, further boosting investor confidence.
- Strong Earnings Expectations: The company is expected to report quarterly earnings of $0.03 per share, representing a 250% year-over-year increase, with revenues projected at $151.5 million, an 11.3% increase from the previous year, showcasing robust performance in the medical device sector.
- Market Dynamics Attention: Although the consensus EPS estimate has remained unchanged over the past 30 days, stock price movements are often correlated with trends in earnings estimate revisions, prompting investors to monitor AtriCure's future earnings dynamics to assess the sustainability of the recent price increase.
See More
QuidelOrtho Partners with Allo Hope Foundation to Enhance Prenatal Care
- Clear Collaboration Goals: QuidelOrtho's partnership with the Allo Hope Foundation aims to enhance prenatal care through education and early testing, particularly addressing maternal red blood cell alloimmunization, a serious and often misunderstood condition, which is expected to significantly improve care quality for underserved populations.
- Educational Resource Development: The two organizations will jointly develop a series of educational materials set to launch this summer, aimed at increasing awareness among healthcare providers and ensuring women receive informed and equitable prenatal testing and care from the outset, which is anticipated to enhance overall patient experience.
- Patient-Centered Commitment: The Allo Hope Foundation emphasizes a patient-centered approach, and through collaboration with QuidelOrtho, combines clinical expertise with lived experiences to provide accurate and compassionate education, striving to support more families earlier in their journey.
- Global Impact Expansion: This collaboration not only enhances QuidelOrtho's influence in maternal health but also promotes global awareness and response to HDFN by increasing public understanding of red blood cell alloimmunization, aiming to standardize survival outcomes for affected children.
See More
QuidelOrtho Partners with Allo Hope Foundation to Enhance Prenatal Care
- Clear Collaboration Goals: QuidelOrtho and the Allo Hope Foundation aim to enhance prenatal care through education, early testing, and stronger connections among laboratory providers, clinicians, and patients, particularly addressing maternal red blood cell alloimmunization issues.
- Focus on Underserved Populations: This partnership seeks to bridge information gaps, providing clear and actionable insights for underserved populations facing challenges in prenatal care, thereby reducing risks associated with a lack of early testing.
- Development of Educational Resources: The organizations plan to release a series of co-produced educational materials this summer, designed to raise awareness among lab technicians and families, ensuring mothers receive timely, accurate testing and support.
- Patient Experience Priority: The Allo Hope Foundation emphasizes the importance of patient experience, and through collaboration with QuidelOrtho, aims to combine clinical expertise with lived experiences to provide more human-centered education and support, making survival for HDFN children the standard.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: Hemolytic disease of the fetus and newborn (HDFN) is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advancements in screening and treatment, gaps in awareness and management persist.
- Podcast Content: Episode 58 of QuidelOrtho's Science Bytes podcast, hosted by Global Product Manager Michelle Mullens, features Bethany Weathersby, Founder of the Allo Hope Foundation, discussing the impact of red blood cell antibodies on pregnancy and the importance of clinical management.
- Importance of Laboratory Testing: The podcast emphasizes the critical role of laboratory testing in prenatal care decisions, highlighting that timely results can significantly improve outcomes for mothers and babies, particularly in well-resourced healthcare settings.
- Global Awareness Initiatives: The Allo Hope Foundation is dedicated to raising global awareness of HDFN, providing patient counseling, facilitating specialty referrals, and conducting disease research to ensure that survival from HDFN becomes a global expectation.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: HDFN is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advances in screening and treatment, inconsistencies in awareness and management persist.
- Impact of Awareness Gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delays in understanding and care, which negatively affects maternal and fetal health, highlighting the need for increased awareness.
- Importance of Laboratory Testing: Antibody screening and titers directly guide pregnancy management and risk assessment, with timely testing results significantly improving health outcomes for mothers and babies.
- Patient Perspective: By connecting diagnostic workflows to real-world outcomes, the discussion emphasizes opportunities to enhance care, particularly in well-resourced healthcare settings where timely access to expertise is crucial.
See More
QuidelOrtho Corporation to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: QuidelOrtho's management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 12:20 PM ET, aiming to attract investor interest in its innovative in vitro diagnostic products.
- Fireside Chat Event: On June 3, 2026, at the Jefferies Global Healthcare Conference, QuidelOrtho's management will participate in a fireside chat at 8:10 AM ET, further showcasing the company's market strategy and future development direction.
- Live Webcast Access: Interested investors can access the live webcast and replay of the conferences through the
See More
